

# Platinum International Health Sciences Fund Investment Strategy

The Platinum International Health Sciences Fund primarily invests in health care companies listed on securities markets around the world. The portfolio will ideally consist of 30 to 80 securities that Platinum believes to be undervalued by the market. Cash may be held when undervalued securities cannot be found. However, the portfolio typically has 50% or more net equity exposure. Platinum may short-sell securities that it considers overvalued.

The fund's key investment guidelines are summarised below. For further details, please refer to the latest [Product Disclosure Statement](#).

<b>Suggested time horizon</b>	5 or more years
<b>Geographic limits</b>	N/A
<b>Industry/sector limits</b>	The fund may invest in companies engaged in the provision of products or services to the health care industry, including but not limited to biotechnology, pharmaceuticals, diagnostics, laboratory technologies, distributors of health care products, equipment and services, hospitals and nursing care, health insurance and information technology providers to such companies.
<b>Number of securities in portfolio</b>	Typically 30 to 80 securities
<b>Net equity exposure</b>	Typically 50% or more of the fund's net asset value
<b>Cash holdings</b>	<ul style="list-style-type: none"> <li>○ Typical range: 0 – 40% of the fund's net asset value</li> <li>○ Permissible range: 0 – 100% of the fund's net asset value</li> </ul>
<b>Limits on individual security holdings</b>	The fund will seldom invest more than 5% of its net asset value in the securities of a single issuer.
<b>Short-selling</b>	Subject to the limits on leverage and the use of derivatives, the fund may short-sell securities and indices for risk management purposes or as a way to take opportunities to increase returns. See Platinum's <a href="#">risk management</a> strategies for further details.
<b>Currency</b>	<ul style="list-style-type: none"> <li>○ The fund's currency exposures are actively managed with the aim of capturing the returns and minimising the risks arising from the fund's exposure to foreign currency fluctuations, which can change the value of the equity investments measured in the fund's reporting currency (AUD).</li> <li>○ Platinum may manage the fund's currency exposures using foreign exchange forwards, swaps, non-deliverable forwards, currency options and spot foreign exchange trades.</li> </ul> <p>See Platinum's <a href="#">risk management</a> strategies for further details.</p>
<b>Leverage</b>	<ul style="list-style-type: none"> <li>○ The fund does not borrow funds (except for short-term overdrafts for trade settlement), though borrowing is permitted under the fund's constitution.</li> <li>○ The fund may be leveraged through the use of derivatives (see below for detail).</li> </ul>
<b>Derivatives</b>	<ul style="list-style-type: none"> <li>○ The fund may use financial derivative instruments for risk management purposes and/or as a way to take opportunities to increase returns, to gain access to markets not readily available to foreign investors and/or to establish short positions.</li> <li>○ Both over-the-counter (OTC) derivatives and exchange-traded derivatives are permitted.</li> </ul>

	<ul style="list-style-type: none"> <li>○ The underlying value of the fund’s derivative positions<sup>1</sup> will not exceed 100% of the fund’s net asset value.</li> <li>○ The fund’s gross exposure, taking into account all physical securities positions and long and short derivatives,<sup>1</sup> will not exceed 150% of the fund’s net asset value.</li> </ul> <p>See Platinum’s <a href="#">risk management</a> strategies for further details.</p> <p><sup>1</sup> Where options are employed, the underlying value will be the Delta-adjusted exposure. “Delta” is the theoretical measure of the sensitivity of the option price to a change in the price of the underlying asset (usually expressed as a percentage).</p>
<b>Securities lending</b>	Not undertaken, although permitted under the fund’s constitution.